Voyager Therapeutics, Inc. has filed an amendment to its previous report regarding its third quarter financial results. The amendment, filed on November 18, 2026, corrects an inadvertent technical error in the submission of the original filing dated November 5, 2026. This correction is significant as it ensures accurate reporting of the company's operations and financial condition.
Voyager Therapeutics, based in Lexington, Massachusetts, is a biotechnology company focused on developing genetic therapies for neurological diseases. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products, excluding diagnostic substances. Voyager trades on the Nasdaq under the ticker symbol VYGR.
The filing states, "This Amendment is being filed solely to correct an inadvertent technical error in the submission of the Original Filing through EDGAR which referenced the incorrect Form 8-K Item Number (Item 2.01) in the EDGAR submission header." The amendment does not change any of the previously reported financial results or operational updates from the original filing.
This update may affect investors and stakeholders who rely on accurate reporting for decision-making. Voyager's commitment to correcting its filings reflects its dedication to transparency and compliance in the highly regulated biotechnology industry.
Looking ahead, the filing does not specify what actions will follow this amendment, but it reinforces the company's ongoing efforts to maintain clarity in its communications with investors and the public.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










